Crescent Biopharma Inc(CBIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -7.65 | Insider Own | 16.78% | Shs Outstand | 37.1M | Perf Week | 1.53% |
| Market Cap | 0.49B | Forward P/E | - | EPS next Y | -5.24% | Insider Trans | 14.07% | Shs Float | 30.9M | Perf Month | -8.67% |
| Enterprise Value | 0.33B | PEG | - | EPS next Q | -0.67 | Inst Own | 70.7% | Short Float | 14.3% | Perf Quarter | -10.16% |
| Income | -0.17B | P/S | 41.49 | EPS this Y | 78.41% | Inst Trans | 12.46% | Short Ratio | 12.63 | Perf Half Y | -44.62% |
| Sales | 0.01B | P/B | 2.31 | EPS next 5Y | 37.95% | ROA | -97.08% | Short Interest | 4.42M | Perf YTD | 11.89% |
| Book/sh | 5.74 | P/C | 2.87 | EPS past 3/5Y | 45.01% 33.26% | ROE | -109.17% | 52W High | -51.59% ($27.41) | Perf Year | 2.08% |
| Cash/sh | 4.62 | P/FCF | - | Sales past 3/5Y | 424.86% 1.31% | ROIC | -100.55% | 52W Low | 52.18% ($8.72) | Perf 3Y | -88.46% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 78.59% | Gross Margin | 98.22% | Volatility(W/M) | 6.12% 7.7% | Perf 5Y | -92.9% |
| Dividend TTM | - | EV/Sales | 27.5 | Sales Y/Y TTM | -100% | Oper. Margin | -1417.74% | ATR (14) | 1.07 | Perf 10Y | -97.82% |
| Dividend Ex-Date | - | Quick Ratio | 9.66 | EPS Q/Q | 85.6% | Profit Margin | -1389.58% | RSI (14) | 43.67 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.66 | Sales Q/Q | - | SMA20 | -0.99% ($13.4) | Beta | 1.38 | Target Price | $31.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/7/30 | SMA50 | -16.05% ($15.81) | Rel Volume | 0.82 | Prev Close | $12.76 |
| Employees | 44 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -0.58% -100% | SMA200 | -16.3% ($15.85) | Avg Volume(3M) | 0.35M | Price | $13.27 |
| IPO | 2014/1/10 | Option/Short | Yes/Yes | Trades | 4264 | Volume | 288,236 | Change | 4% |
🧬 A US clinical-stage biotechnology company developing innovative oncology therapeutics for cancer treatment. It has a pipeline of bispecific antibody candidates that simultaneously target immune checkpoint inhibitors and vascular endothelial growth factor, along with next-generation antibody-drug conjugates (ADC technology). The company is currently in the research and development stage with no product sales, and is advancing clinical development of its drug candidates through strategic partnerships with global pharmaceutical companies.
Over the past 1 year, on the lower side
52% below its 1-year high.
Traded about as much as usual. That is 82% of its average volume.
CBIO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +78.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4,149. Peers typically go for $1,261.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -92.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 70.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #219 of 594 in the industry
Based on market cap of $493M.
BLSM#217 BlossomHill Therapeutics Inc $501M PER - 
FTH#218 Faeth Therapeutics Inc $494M PER - CBIO#219 Crescent Biopharma Inc $493M PER - 
ARVN#220 Arvinas Inc $487M PER 46.5 
PHAT#221 Phathom Pharmaceuticals Inc $485M PER - 
FAQ
What kind of company is CBIO?
CBIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CBIO?
The market cap of CBIO is approximately $493M, ranking 3,169 within its sector.
What is the 52-week high and low for CBIO?
CBIO has recorded a 52-week high of $27.41 and a low of $8.72.
